#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3046	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2593	278.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1577	1577	C	391	C,A	363,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5088	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3989	303.1	0	.	n	.	0	T695C	SNP	695	695	T	1251	1251	C	361	C	332	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5088	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3989	303.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1893	1893	A	380	A,C	358,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5088	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3989	303.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2527	2527	C	362	C,A,T	330,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5088	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3989	303.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2601	2601	A	358	A	335	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5088	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3989	303.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3153	3153	C	391	C,A	359,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	268	folP	855	855	100.0	folP.l15.c4.ctg.1	2032	32.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1296	1298	AGC	42;42;42	A,G;G;C	37,1;38;38	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	690	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3808	43.7	1	SNP	p	S91F	1	.	.	271	273	TTC	717	719	TTC	43;43;43	T;T;C	39;36;40	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	690	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3808	43.7	1	SNP	p	G95N	0	.	.	283	285	GGC	729	731	GGC	44;44;44	G;G,A;C	41;39,1;38	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	690	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3808	43.7	1	SNP	p	D95G	1	.	.	283	285	GGC	729	731	GGC	44;44;44	G;G,A;C	41;39,1;38	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	234	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1831	31.5	1	SNP	p	G45D	1	.	.	133	135	GAC	784	786	GAC	52;52;52	G;A;C	47;44;45	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	152	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1494	25.0	0	.	n	.	0	A197.	DEL	197	197	A	769	769	A	49	A	48	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	676	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3357	48.4	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	755	757	AAC	58;58;57	A,C;A;C	38,2;47;56	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	676	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3357	48.4	1	SNP	p	S87W	0	.	.	259	261	AGT	758	760	AGT	57;57;58	A,C;G;T,G	53,3;53;52,2	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	676	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3357	48.4	1	SNP	p	S87I	0	.	.	259	261	AGT	758	760	AGT	57;57;58	A,C;G;T,G	53,3;53;52,2	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	676	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3357	48.4	1	SNP	p	S87R	0	.	.	259	261	AGT	758	760	AGT	57;57;58	A,C;G;T,G	53,3;53;52,2	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	676	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3357	48.4	1	SNP	p	S88P	0	.	.	262	264	TCC	761	763	TCC	58;59;59	T;C,T,G;C	53;53,2,1;54	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	602	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3286	43.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1942	1944	GGC	53;53;56	G;G;C	46;45;41	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1511	1513	GCA	91;91;91	G,A;C,G,A;A	79,1;78,1,1;79	penA.13.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1514	1516	ATC	89;89;89	A,G;T;C	81,1;83;83	penA.13.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1526	1528	GTG	87;87;87	G;T,G;G	79;77,1;80	penA.13.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1526	1528	GTG	87;87;87	G;T,G;G	79;77,1;80	penA.13.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2030	2032	ACC	48;48;47	A;C;C	40;45;45	penA.13.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2084	2086	GTG	46;46;46	G,T;T,G;G,T	38,1;34,5;33,1	penA.13.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2084	2086	GTG	46;46;46	G,T;T,G;G,T	38,1;34,5;33,1	penA.13.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2207	2209	GGC	47;47;49	G;G;C,T	45;45;43,3	penA.13.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2216	2218	GGC	44;44;42	G;G;C	41;37;25	penA.13.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	602	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2531	56.8	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2234	2236	TCG	41;43;43	T,G;C;G	25,1;33;38	penA.13.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	800	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3586	52.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1818	1820	CCG	80;80;79	C,G,T;C;G,C	66,3,1;75;57,5	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	302	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2372	30.6	0	.	p	.	0	A17T	NONSYN	49	51	GCA	600	602	ACA	35;35;35	A;C;A	30;30;30	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	302	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2372	30.6	0	.	p	.	0	S22G	NONSYN	64	66	AGC	615	617	GGC	36;36;36	G;G;C	32;32;31	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	302	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2372	30.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	797	797	C	30	C	24	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	593	595	GGA	64;63;63	G;G;A	58;55;58	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	710	712	GCT	69;68;68	G;C;T,G	60;61;63,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	716	718	AGC	68;68;67	A;G;C,A	62;65;60,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	878	880	CAA	72;72;73	C;A,C;A	67;67,1;70	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	902	904	GCA	66;66;66	G;C;A,T	64;62;62,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1010	1012	CAA	70;70;70	C;A;A	62;62;62	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	N189S	NONSYN	565	567	AAC	1016	1018	AGC	68;68;68	A,G;G;C	58,1;61;58	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	0	.	p	.	0	Y212fs	FSHIFT	634	634	T	1085	1085	T	56	T	54	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	1	SNP	p	G120K	1	.	.	358	360	AAG	809	811	AAG	62;62;64	A;A;G	60;60;61	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	1	SNP	p	A121D	1	.	.	361	363	GAC	812	814	GAC	65;64;64	G;A;C,T	61;60;58,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	434	porB1b	1041	1041	98.08	porB1b.l6.c4.ctg.1	2139	48.1	1	SNP	p	D121N	0	.	.	361	363	GAC	812	814	GAC	65;64;64	G;A;C,T	61;60;58,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	1732	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	5031	81.5	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2054	2056	AAT	90;90;90	A;A;T	81;82;81	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	256	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1493	41.7	1	SNP	p	V57M	1	.	.	169	171	ATG	789	791	ATG	96;96;97	A;T;G,T	87;88;88,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
